Signals, Powered By EquityPandit
Glenmark Pharmaceutical has entered into an agreement with Celon Pharma, Poland based company for developing and marketing a generic version of GlaxoSmithKline’s Seretide Accuhaler in Europe, which is used for the treatment of lung diseases.
Glenmark said in a statement that Glenmark Pharmaceuticals Europe Ltd has entered into a strategic development and licensing agreement with Celon Pharma SA to develop and market a generic version of GSK’s Seretide Accuhaler product – fluticasone and salmeterol dry powder inhaler in Europe upon commercialisation.
It further added that “As per the terms of the agreement, Glenmark has obtained semi-exclusive marketing and distribution rights of the product across 15 European countries including Great Britain, Germany, Belgium, the Netherlands, Italy, Sweden, Norway and Romania, among others.”
